Trial Search Results
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.
Stanford is currently not accepting patients for this trial.
Kadmon Corporation, LLC
- Drug: XL647
- Histologically confirmed diagnosis of unresectable Stage IIIB or Stage IV relapsed or
- Subjects must have:
1. documented (radiological or clinical) progressive disease (PD) following a prior
response (including stable disease) to monotherapy with erlotinib or gefitinib
that was administered for at least 12 weeks prior to progression OR
2. a documented T790M EGFR mutation
- Measurable disease defined according to RECIST
- ECOG performance status of 0 or 1.
- Sexually active subjects must use an accepted method of contraception during the
course of the study.
- Female subjects of childbearing potential must have a negative pregnancy test at
- Received radiation to ≥25% of his or her bone marrow within 30 days of XL647
- Received erlotinib or gefitinib, or other anticancer therapy within 14 days of the
first dose of study drug.
- Received an investigational drug (excluding erlotinib or gefitinib) within 30 days of
the first dose of study drug.
- Receiving anticoagulation therapy with warfarin.
- Not recovered to Grade ≤1 from adverse events (AEs) due to antineoplastic agents,
investigational drugs, or other medications that were administered prior to study
- Corrected QT interval (QTc) of >0.45 seconds.
- Progressive, symptomatic, or hemorrhagic brain or leptomeningeal metastases.
- Requires steroid or anticonvulsant therapy for the treatment of brain metastases.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study